Back to top
more

Alexion Pharmaceuticals, Inc. (ALXN)

(Delayed Data from NSDQ)

$136.69 USD

136.69
978,618

+3.56 (2.67%)

Updated May 3, 2019 04:00 PM ET

After-Market: $136.70 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Will Trikafta Drive Vertex's (VRTX) Revenues in Q4 Earnings?

by Zacks Equity Research

On Vertex's (VRTX) fourth-quarter earnings call, investor focus will be on the sales performance of its triple combo CF drug Trikafta.

Vertex's (VRTX) Trikafta NDA Gets Priority Review by FDA

by Zacks Equity Research

Vertex's (VRTX) sNDA seeking approval for Trikafta to treat cystic fibrosis in children has been accepted by the FDA.

ALXN vs. BMRN: Which Stock Should Value Investors Buy Now?

by Zacks Equity Research

ALXN vs. BMRN: Which Stock Is the Better Value Option?

J&J (JNJ) Q4 Earnings & Sales Beat, 2021 Guidance Upbeat

by Zacks Equity Research

J&J (JNJ) beats fourth-quarter 2020 estimates for both earnings and sales. It issues its adjusted earnings and sales outlook for 2021. Stock up.

BioCryst (BCRX) Wins Japanese Approval for HAE Drug Orladeyo

by Zacks Equity Research

BioCryst (BCRX) gets approval in Japan for oral, once-daily Orladeyo 150 mg for prophylactic treatment of hereditary angioedema (HAE) in adults and pediatric patients 12 years or older.

Ultragenyx's (RARE) IND for Wilson Disease Cleared by FDA

by Zacks Equity Research

Ultragenyx's (RARE) IND application for UX701 for the treatment of Wilson Disease gets FDA clearance.

Urmimala Biswas headshot

5 Finest PEG Stocks for GARP Investors

by Urmimala Biswas

Here are five picks out of 45 top-ranked stocks with discounted PEG.

Will Alexion (ALXN) Beat Estimates Again in Its Next Earnings Report?

by Zacks Equity Research

Alexion (ALXN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Roche's (RHHBY) Esbriet sNDA Gets Priority Review From FDA

by Zacks Equity Research

The FDA accepts Roche's (RHHBY) sNDA for Esbriet under a priority review to treat unclassifiable interstitial lung disease. A verdict from the regulatory body is awaited in May 2021.

AstraZeneca's (AZN) Enhertu Gets EU Nod for Breast Cancer

by Zacks Equity Research

AstraZeneca's (AZN) Enhertu gets EU approval for metastatic HER2-positive breast cancer patients who have received two or more prior anti-HER2-based regimens.

Cocrystal Pharma (COCP) Completes Research Obligations With Merck

by Zacks Equity Research

Cocrystal (COCP) completes all research obligations under the Merck exclusive worldwide license and collaboration agreement.

Biotech Stock Roundup: ALXN Pauses Study, ACRS & GRTS Surge, & Other Updates

by Zacks Equity Research

The biotech sector was in focus last week with regulatory and pipeline updates from quite a few companies like Alexion (ALXN), Aclaris (ACRS) and Biohaven (BHVN).

AstraZeneca's (AZN) Enhertu Gets FDA Nod for Gastric Cancer

by Zacks Equity Research

AstraZeneca's (AZN) Enhertu is the first HER2-directed medicine approved in a decade for patients with HER2-positive metastatic gastric cancer.

Zacks.com featured highlights include: Alexion Pharmaceuticals, Adient, Affiliated Managers Group and General Motors

by Zacks Equity Research

Zacks.com featured highlights include: Alexion Pharmaceuticals, Adient, Affiliated Managers Group and General Motors

Pfizer's (PFE) Xalkori Gets FDA Nod for Rare Lymphoma in Kids

by Zacks Equity Research

FDA approves Pfizer's (PFE) Xalkori for relapsed or refractory ALK-positive anaplastic large cell lymphoma, a rare form of non-Hodgkin lymphoma (NHL), in pediatric patients and young adults.

Alexion (ALXN) to Pause Enrollment in COVID-19 Study on Ultomiris

by Zacks Equity Research

Alexion (ALXN) decides to stop further enrollment in the late-stage study of Ultomiris in adults with severe COVID-19 requiring mechanical ventilation due to lack of efficacy.

Kinjel Shah headshot

4 Promising Price-to-Book Value Stocks to Buy Now

by Kinjel Shah

P/B ratio is emerging as a convenient tool to identify low-priced stocks that have high growth prospects.

AbbVie (ABBV) Inks Deal to Acquire Medical Device Company

by Zacks Equity Research

AbbVie (ABBV) signs an agreement to acquire privately held Cypris Medical, including the latter's Xact device which is used for performing face and neck lifts.

Merck (MRK) Gets Priority Tag for Pneumococcal Vaccine BLA

by Zacks Equity Research

Merck's (MRK) investigational 15-valent pneumococcal conjugate vaccine, V114 includes pneumococcal serotypes 22F and 33F, which are not included in the currently licensed conjugate vaccines.

Sanofi (SNY) to Acquire Kymab to Boost Immunology Presence

by Zacks Equity Research

Sanofi's (SNY) potential acquisition of Kymab, a private biotech, is set to strengthen its presence in immunology.

ALXN or BMRN: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

ALXN vs. BMRN: Which Stock Is the Better Value Option?

Apellis' (APLS) Pipeline Candidate Pegcetacoplan Promising

by Zacks Equity Research

Apellis' (APLS) lead pipeline candidate, pegcetacoplan, is a promising one and being developed for several indications.

Ekta Bagri headshot

5 Biotech Stocks That More Than Doubled This Year

by Ekta Bagri

The biotech sector has been in focus through 2020 as companies like Moderna (MRNA) strive hard to develop a vaccine for COVID-19.

Kinjel Shah headshot

Pharma Stock Roundup: FDA Emergency Nod to PFE/BNTX COVID-19 Vaccine, AZN to Buy ALXN

by Kinjel Shah

FDA grants approval for emergency use of Pfizer's (PFE) COVID-19 vaccine. AstraZeneca (AZN) offers to buy Alexion.

Biotech Stock Roundup: ALXN Up on Acquisition News, PFE-BNTX Get EUA for Vaccine & More

by Zacks Equity Research

Coronavirus vaccine updates from Moderna (MRNA) and Pfizer (PFE)/BioNTech (BNTX) and Alexion's (ALXN) acquisition grab headlines this week.